Dr Saoirse Dolly

Dr Saoirse Dolly is as a Consultant Medical Oncologist who specialises in Rapid Diagnostics and Cancer Treatment.

She offers appointments for Rapid Diagnostics and Cancer Treatment in London, Brighton and online

To book an appointment please email her PA on drdolly@thelondonclinic.co.uk

1. Rapid Diagnostics

Dr Dolly offers a 45 minute consultation that focuses on symptoms, medical problems, medications with a full examination and plan for what tests are best suited for you. She then  coordinates  the tests and interprets  the results, with an aim of finding a diagnosis or to offer reassurance if these tests are clear.

2. Cancer care for Neuroendocrine tumours, GIST, Oesphagus, Stomach, Small bowel, Pancreas, bile ducts and liver cancers

Background

Following the completion of her specialist training in 2018, Dr Dolly was appointed as Medical Oncology Consultant at the Academic Health Centres of Guy’s and St Thomas’ and Kings College Hospitals. In recognition of her expertise and dedication to academia, she was appointed as an Honorary Senior Lecturer at the School of Cancer & Pharmaceutical Science, King’s College London, in 2021. She now works at University Hospitals Sussex  NHS Foundation  Trust and is the Clinical Lead for the Non Site Specific symptom pathway in Surrey and Sussex.

Research

Alongside her clinical work, Dr Dolly's research interests include

Earlier cancer diagnosis and health innovation:

She has published many articles on the effectivenss of Rapid Diagnostic Clinics and won the HSJ award in 2020 for the Best Integrated Healthcare Partnership. Dr Dolly chairs the Cancer Diagnostics and Innovation symposium at the Oncology Forum. She was the National Clinical Lead for the NHS Galleri trial multi-cancer early detection test.

Real-world evidence :

Dr Dolly is passionate about showing how effective cancer treatments are for patients treated in the real world (so outside of clinical trials). She has published over 40 articles showing it was safe to continue cancer treatment during the COVID-19 pandemic. She has designed databases in neuroendocrine, pancreatic, biliary, and small bowel cancers, as well as a national registry for rare liver tumours.

New cancer drug targets:  PhD  at the Institute of Cancer Research in 2013.